[Histomorphological changes in newborn rat lung induced by maternal sugar intake]. / Cambios histomorfológicos en pulmón de rata recién nacida inducidos por ingesta materna de azúcar.

INTRODUCTION: Respiratory conditions are the most common reason for admission to the neonatal unit for both term and premature newborns. It is known that nutritional imbalances during pregnancy affect the maturation and functional capacity of organs. OBJECTIVE: to describe the pulmonary histomorpholo- gy of newborn rats due to maternal sugar intake by light microscopy. MATERIAL AND METHOD: Twenty 4-week-old female Wistar rats divided into control and experimental groups with sucrose before and during pregnancy were used. At week 15, the females mated with males overnight. We recorded va lues from the body and lung weight of the newborns. The lungs were stained using Hematoxylin and Eosin, Masson's trichrome, Periodic acid-Schiff, and Verhoeff. RESULTS: Newborns from the experi mental group presented significantly lower body and lung weight (6.980 ± 0.493* g, 0.164 ± 0.022* g; *p < 0,05) compared with controls (7.854 ± 0.497 g, 0.189 ± 0.005 g). The lungs of the experimental group showed structural alterations in the lung parenchyma, as well as changes in glycogen deposits, collagen fibers, and elastin compared with the control group. CONCLUSION: Alterations in newborn lung growth and development are associated with maternal sucrose intake. It is important to re member that interventions on the maternal diet have beneficial effects for both the mother and the newborn.

Antidiabetic, antidyslipidemic and toxicity profile of ENV-2: A potent pyrazole derivative against diabetes and related diseases.

Diabetes is a major health problem and a predisposition factor for further degenerative complications and, therefore, novel therapies are urgently needed. Currently, cannabinoid receptor 1 (CB1 receptor) antagonists have been considered as promissory entities for metabolic disorders treatment. Accordingly, the purpose of this work was the evaluation of the sub-acute antidiabetic, anti-hyperglycemic, antidyslipidemic and toxicological profile of ENV-2, a potent hypoglycemic and antioxidant CB1 receptor antagonist. In this study, ENV-2 showed a pronounced anti-hyperglycemic effect even at a dose of 5mg/kg (P<0.05) in a glucose tolerance test on normoglycemic rats. Moreover, after administration of ENV-2 (16mg/kg) to diabetic rats, a prominent antidiabetic activity was observed (P<0.05), which was higher than glibenclamide. Sub-acute treatment (10 days) of ENV-2 resulted in a significant reduction of plasma glucose (P<0.05). Also, the levels of peripheral lipids were improved; blood triacylglycerols (TG) and cholesterol (CHOL) were diminished (P<0.05). In addition, it was found that ENV-2 reduced IL-1ß and IL-18 mRNA expression in adipose tissue (P<0.05). Due to the satisfactory outcomes, we were interested in evaluating the toxicity of ENV-2 in both acute and sub-chronic approaches. Regarding the acute administration, the compound resulted to be non-toxic and was grouped in category 5 according to OECD. It was also found that sub-chronic administration did not increase the size of the studied organs, while no structural damage was observed in heart, lung, liver and kidney tissues. Finally, neither AST nor ALT damage hepatic markers were augmented.